A ~100,000-patient US SCD population narrows to a 55,000-65,000 addressable white space, but actual gene-therapy uptake still lags projections by 2 to 3 times, and that gap, not prevalence, is what a launch plan must size against.
Two independent methods size the US sickle cell disease population, and they answer different questions. The epidemiology method starts from disease incidence: roughly 100,000 Americans have SCD, about 1 in 365 Black or African American births, split across HbSS (60-65%), HbSC (about 25%), and HbS/beta-thalassemia (the remainder) by severity. Layering severity onto that base narrows the population fast: an estimated 20,000 to 30,000 patients have severe, recurrent vaso-occlusive disease and are clinically relevant for gene therapy in the first place. The claims-based method starts from treatment patterns instead, using IQVIA prescription-claims data and the Medicaid Cell and Gene Therapy Access Model's state-adoption tracker to identify patients with no adequate current therapy: 15,000 to 20,000 hydroxyurea-inadequate or -intolerant patients, plus more than 40,000 gene-therapy-ineligible patients, a combined 55,000 to 65,000-patient white space.
Neither number is the one that should drive a launch plan. Actual gene-therapy uptake in the first 12 months post-launch came to an estimated 50 to 100 combined Casgevy and Lyfgenia patients, against pre-launch projections of 200 to 300, a two-to-three-fold shortfall against even the narrowest eligible estimate. That gap is not a sizing error. It traces to HSCT-qualified-center capacity, the slow pace of state-by-state Medicaid CGTA contract adoption, and physicians and patients waiting on longer-term durability data before committing to a one-time, irreversible therapy. Our sensitivity analysis ranks these capacity and contracting constraints above raw epidemiology as the dominant driver of near-term treated volume, the opposite of what a naive top-down model would assume.
US sickle cell sizing — epidemiology, claims, and actual treated volume compared
| Sizing Method | Population Estimate | Source |
|---|---|---|
| Epidemiology-based (total prevalence) | ~100,000 patients | Hassell, Am J Prev Med 2010 (PMID 20331952) |
| Epidemiology-based (severe/gene-therapy-relevant) | 20,000–30,000 patients | Genotype-based severity segmentation |
| Claims-based (addressable white space) | 55,000–65,000 patients | IQVIA SCD Rx claims data; Medicaid CGTA state-adoption tracker |
| Actual treated (yr 1 post-launch) | 50–100 patients | Vertex/bluebird bio commercial updates |
Sources: Hassell KL, Am J Prev Med 2010 (PMID 20331952); IQVIA SCD Rx claims data 2024; Medicaid CGTA state adoption tracker; Vertex/bluebird bio commercial updates.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Genotype-based severity segmentation methodology
- the IQVIA claims and Medicaid CGTA tracker basis for the white-space estimate
- how the two methods triangulate rather than average
Delivers
- HSCT-centre capacity and Medicaid CGTA state-adoption-pace analysis
- durability-data-driven physician and patient hesitancy
- sensitivity ranking of capacity constraints above raw epidemiology
Delivers
- Sensitivity ranking of every input
- why HSCT-centre and Medicaid-contracting capacity outranks epidemiology as the binding near-term constraint
- scenario ranges tied to capacity expansion
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why treatment capacity, not prevalence, is the assumption that determines whether the near-term total holds up
- Pressure-tested against the 50-100-vs-200-300 uptake gap before the rest of the model is built out
- US SCD prevalence (~100,000) and genotype-based severity segmentation
- The 20,000-30,000 severe, gene-therapy-relevant subset
- IQVIA prescription-claims data and the Medicaid CGTA state-adoption tracker
- The 55,000-65,000-patient addressable white space this implies
- Where the epidemiology-based and claims-based methods agree and diverge
- Treatment capacity as the explanation for the actual-vs-projected uptake gap
- Treatment capacity and Medicaid-contracting pace ranked above raw prevalence
- Scenario ranges tied to HSCT-centre-capacity expansion
- The full triangulated model, re-runnable with your own assumptions
- The open sizing questions your team must close before the number is used in planning
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx market sizing model triangulates at least two independent methods, epidemiology-based and claims/registry-based, before accepting a patient count. This is explicitly a sizing model (static patient count), distinct from a Patient Flow or forecasting model (dynamic revenue/uptake).
Sickle cell disease US sizing sources: Hassell KL, Am J Prev Med 2010 (PMID 20331952), IQVIA SCD prescription-claims data 2024, the Medicaid CGTA state-adoption tracker, and Vertex/bluebird bio commercial updates on actual gene-therapy uptake.
- US SCD prevalence and genotype-based severity segmentation verified against Hassell KL, Am J Prev Med 2010 (PMID 20331952)
- Claims-based addressable white space verified against IQVIA SCD Rx claims data and the Medicaid CGTA state-adoption tracker
- Actual gene-therapy uptake in the first 12 months verified against Vertex/bluebird bio commercial updates
Frequently asked questions
Commission this model
AXLRx delivers rare disease market sizing models built for forecasting and strategy teams sizing the US sickle cell disease opportunity. Custom model in 72 hours.
Specify your indication, market, and cohort definition.
AXLRx analyst confirms triangulation methods and comparator set before building.
Research-verified sizing model in 72 hours with optional analyst readout.